Dafna Capital Management LLC Scynexis Inc Transaction History

Dafna Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.46 - $2.94 $358,860 - $722,637	-245,795 Reduced 61.59%	153,269 $239,000
Q3 2022 Nov 14, 2022	SELL	$1.83 - $2.93 $101,433 - $162,404	-55,428 Reduced 12.2%	399,064 $958,000
Q2 2022 Aug 15, 2022	BUY	$1.77 - $3.87 $589,852 - $1.29 Million	333,250 Added 274.86%	454,492 $845,000
Q4 2021 Feb 14, 2022	BUY	$4.94 - $7.69 $598,935 - $932,350	121,242 New	121,242 $740,000
Q2 2021 Aug 16, 2021	SELL	$6.5 - $9.97 $584,181 - $896,043	-89,874 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.93 - $9.63 $763,173 - $1.06 Million	-110,126 Reduced 55.06%	89,874 $714,000
Q4 2020 Feb 16, 2021	BUY	$4.28 - $7.87 $856,000 - $1.57 Million	200,000 New	200,000 $1.53 Million

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $40.5M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.